Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

ALYMSYS

BEVACIZUMAB-MALY

Standard Dose
400MG/16ML(25MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ALYMSYS is listed in Drugs@FDA under application 761231 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BEVACIZUMAB-MALY Form and strength INJECTABLE;INJECTION - 400MG/16ML(25MG/ML Sponsor AMNEAL PHARMS LLC Submission history Latest submission status date: 2022-04-13 00:00:00.

Structured Monograph

Clinical summary

Approval overview ALYMSYS is listed in Drugs@FDA under application 761231 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient BEVACIZUMAB-MALY Form and strength INJECTABLE;INJECTION - 400MG/16ML(25MG/ML Sponsor AMNEAL PHARMS LLC Submission history Latest submission status date: 2022-04-13 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.